Pulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because of its nonspecific signs and symptoms. PE is also an important potential risk of osimertinib treatment, however, clinical courses regarding retreatment after osimertinib-induced acute pulmonary embolism remain unclear. We described a 77-year-old woman with postoperative recurrent lung adenocarcinoma who developed osimertinib-induced acute PE. She received apixaban and was later successfully retreated with osimertinib. This case suggests that retreatment with osimertinib after osimertinib-induced acute PE may be a treatment option when alternative therapeutic options are limited
Lessons learned: Osimertinib has confirmed effectiveness in this real-world population of patients w...
We describe a patient with breast cancer who relapsed with an extensive pulmonary lymphovascular tum...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
AbstractPulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because o...
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rec...
Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers....
Drug-induced interstitial lung disease (DI-ILD) is a rare, yet life-threatening complication associa...
Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used p...
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line tre...
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in ...
National audienceThe third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as ...
Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastati...
Cancer therapeutics-related cardiac dysfunction is currently of great concern as one of the pivotal ...
We would like to share an unusual case of a 61- year-old female with a known history of breast carci...
This case demonstrates the therapeutic challenges encountered when managing an acute pulmonary embol...
Lessons learned: Osimertinib has confirmed effectiveness in this real-world population of patients w...
We describe a patient with breast cancer who relapsed with an extensive pulmonary lymphovascular tum...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
AbstractPulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because o...
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rec...
Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers....
Drug-induced interstitial lung disease (DI-ILD) is a rare, yet life-threatening complication associa...
Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used p...
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line tre...
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in ...
National audienceThe third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as ...
Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastati...
Cancer therapeutics-related cardiac dysfunction is currently of great concern as one of the pivotal ...
We would like to share an unusual case of a 61- year-old female with a known history of breast carci...
This case demonstrates the therapeutic challenges encountered when managing an acute pulmonary embol...
Lessons learned: Osimertinib has confirmed effectiveness in this real-world population of patients w...
We describe a patient with breast cancer who relapsed with an extensive pulmonary lymphovascular tum...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...